Grupo Financiero Galicia S.A. (GGAL) Reaches $59.65 52-Week High; Cancer Genetics (CGIX) SI Increased By 2.95%

December 7, 2017 - By Vivian Park

The stock of Grupo Financiero Galicia S.A. (NASDAQ:GGAL) hit a new 52-week high and has $61.44 target or 3.00% above today’s $59.65 share price. The 5 months bullish chart indicates low risk for the $8.06B company. The 1-year high was reported on Dec, 7 by Barchart.com. If the $61.44 price target is reached, the company will be worth $241.65M more. The stock increased 0.03% or $0.02 during the last trading session, reaching $59.65. About 252,163 shares traded. Grupo Financiero Galicia S.A. (NASDAQ:GGAL) has risen 63.44% since December 7, 2016 and is uptrending. It has outperformed by 46.74% the S&P500.

Cancer Genetics Incorporated (NASDAQ:CGIX) had an increase of 2.95% in short interest. CGIX’s SI was 1.27 million shares in December as released by FINRA. Its up 2.95% from 1.23M shares previously. With 116,700 avg volume, 11 days are for Cancer Genetics Incorporated (NASDAQ:CGIX)’s short sellers to cover CGIX’s short positions. The SI to Cancer Genetics Incorporated’s float is 9.45%. The stock increased 4.65% or $0.1 during the last trading session, reaching $2.25. About 40,343 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has risen 81.82% since December 7, 2016 and is uptrending. It has outperformed by 65.12% the S&P500.

Among 3 analysts covering Grupo Financiero Galicia (NASDAQ:GGAL), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Grupo Financiero Galicia has $32 highest and $31 lowest target. $31.50’s average target is -47.19% below currents $59.65 stock price. Grupo Financiero Galicia had 5 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Grupo Financiero Galicia S.A. (NASDAQ:GGAL) has “Neutral” rating given on Tuesday, February 9 by JP Morgan. The firm earned “Buy” rating on Friday, August 7 by Zacks. The rating was upgraded by Citigroup on Monday, August 22 to “Neutral”. The firm has “Neutral” rating by Credit Suisse given on Tuesday, March 29. The stock of Grupo Financiero Galicia S.A. (NASDAQ:GGAL) earned “Outperform” rating by Credit Suisse on Friday, October 28.

Grupo Financiero Galicia S.A., a financial services holding company, provides various financial services and products in Argentina. The company has market cap of $8.06 billion. The firm operates through Banking, Regional Credit Cards, CFA Personal Loans, Insurance, and Other Grupo Galicia Businesses divisions. It has a 181.31 P/E ratio. It offers corporate banking services to companies, and the agricultural and livestock sector; foreign trade transactions; corporate debt and securitization transactions; and e-banking services.

Investors sentiment decreased to 1.17 in Q2 2017. Its down 1.54, from 2.71 in 2017Q1. It fall, as 6 investors sold Cancer Genetics, Inc. shares while 6 reduced holdings. 5 funds opened positions while 9 raised stakes. 2.76 million shares or 20.57% more from 2.29 million shares in 2017Q1 were reported. Barclays Public Ltd owns 454 shares or 0% of their US portfolio. Blackrock holds 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX) for 42,370 shares. Deutsche Financial Bank Ag holds 0% or 300 shares in its portfolio. Next Financial Incorporated owns 2,500 shares for 0% of their portfolio. Eagle Global Advsr Limited Liability Co invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Northern has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Geode Cap Mgmt Ltd accumulated 87,279 shares. 5,276 are held by Royal Bank Of Canada. Jacobs Levy Equity Mgmt has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Thompson Davis And Inc has invested 0.71% in Cancer Genetics, Inc. (NASDAQ:CGIX). Moreover, Vanguard Gru Incorporated has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX) for 516,785 shares. Wells Fargo And Mn has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Renaissance Technology Ltd Liability Corporation has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). National Bank & Trust Of America Corporation De accumulated 0% or 625 shares. Fincl Bank Of Montreal Can holds 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX) for 29,228 shares.

Among 6 analysts covering Cancer Genetics (NASDAQ:CGIX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Cancer Genetics had 8 analyst reports since March 11, 2016 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Tuesday, August 15. The firm has “Neutral” rating by Janney Capital given on Friday, March 11. The firm earned “Buy” rating on Wednesday, November 29 by H.C. Wainwright. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Tuesday, March 15 by Aegis Capital. The stock has “Buy” rating by H.C. Wainwright on Thursday, September 21. The firm earned “Buy” rating on Monday, September 26 by Rodman & Renshaw.

Since June 12, 2017, it had 1 insider buy, and 0 selling transactions for $374,870 activity. $374,870 worth of Cancer Genetics, Inc. (NASDAQ:CGIX) shares were bought by PAPPAJOHN JOHN.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com